The personalized medicine era demands better prediction of which cancer treatments will succeed for individual patients. This comprehensive analysis of nearly 6,000 breast cancer cases reveals that inherited genetic variants don't just influence initial tumor development—they actively shape how cancers evolve resistance to specific therapies.
Patients carrying germline BRCA2 mutations demonstrate a remarkably consistent resistance pathway when treated with CDK4/6 inhibitors, the current standard frontline therapy. These tumors systematically lose RB1 function through a two-step mechanism: they begin treatment with only one working copy of the RB1 gene (hemizygosity), making complete loss easier to achieve, while ongoing DNA repair defects accelerate the acquisition of resistance-driving mutations under treatment pressure. Laboratory models confirmed this pattern, showing near-universal CDK4/6 inhibitor failure accompanied by RB1 loss.
This finding challenges current treatment sequencing in BRCA2 carriers, where CDK4/6 inhibitors are typically used first-line despite their predictable failure. PARP inhibitors consistently outperformed CDK4/6 inhibitors across multiple models and clinical datasets, suggesting a fundamental reordering of treatment priorities may be warranted. The research establishes a broader framework for resistance prediction based on baseline genetic architecture—patients enter treatment with predetermined evolutionary constraints that dictate which resistance pathways are accessible. Rather than waiting for resistance to emerge, oncologists could potentially forecast and circumvent specific failure modes by matching initial therapy selection to each patient's genetic resistance landscape, fundamentally shifting from reactive to anticipatory treatment strategies.